RNS Number : 6521K
  Medgenics Inc
  23 December 2008
   
    Medgenics, Inc.
('Medgenics' or the 'Company')

    Issue of Patent

    MEDGENICS' BIOPUMP PROTEIN THERAPY
TECHNOLOGY APPROVED FOR PATENT IN THE USA    
    Misgav, Israel and London, UK - 23 December, 2008 - Medgenics (AIM: MEDG) is pleased to announce that it has received formal
notification from the United States Patent and Trade Mark Office that a patent will be issued on 23 December 2008 for the key claims
covering a core element of its Biopump protein therapy technology. These claims are the most important to the protection of the Company's
core dermis biopump technology.
    Commenting on the notification that the patent had been approved, Dr. Andrew Pearlman, CEO said: 
    "This patent represents a significant milestone in protecting the key elements of the Company's intellectual property in the United
States, the Company's largest target market for the Biopump Platform Technology.  
    The Phase I/II clinical trial is proceeding well. The Directors remain cautiously optimistic that the ongoing trial will continue to
support the Directors' belief in this breakthrough platform technology for the sustained treatment of anemia. This patent will enhance
significantly the Company's ability to make the biopump a commercial success as well as a medical one."
    Patent number 7468242 will be issued on 23 December 2008 for the Company's application (application number 10/834,345). This patent
relates to "dermal micro-organs, methods and apparatuses for producing and using the same" and the patent application was made in April
2004.
    Additional claims from the same application are under review by the USPTO, and applications for patents with similar claims are pending
in other key jurisdictions.

    For further information, contact:

 Medgenics, Inc.                                        Phone: +972 4 902 8900
 Dr. Andrew L. Pearlman                                                       
  
 Grayling Global (Financial PR, UK)                    Phone: +44 7900 053 536
 Jonathan Shillington                                                         
 Alistair Scott                          jonathan.shillington@uk.grayling.com 
  
 Blomfield Corporate Finance Limited                   Phone: +44 207 489 4500
 (Nominated Adviser)                                                          
 James Pinner
 Alan MacKenzie
  
 SVS Securities plc (Broker)                           Phone: +44 207 638 5600
 Peter Manfield                                                               
 Ian Callaway
  
 United States contacts:                                                      
  Grayling Global (Investor Relations)                  Phone: +1 646 284 8472
 Leslie Wolf-Creutzfeldt                          lwolf-creutzfeldt@hfgcg.com 
                                                                              
 Grayling Global (Media Relations)                      Phone: +1 646 284 9455
 Ivette Almeida                                            ialmeida@hfgcg.com 
                                                                              


    NOTES TO EDITORS:
    Medgenics, Inc. is a clinical-stage biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide
sustained-action protein therapy for the treatment of a range of chronic diseases. 
    Medgenics currently has two products in development based on this technology: 
    *     EPODURE - producing erythropoietin (EPO) to treat anemia
    *     INFRADURE - producing interferon-alpha (IFN-*) to treat hepatitis C 
    The Company has demonstrated proof of principle of the Biopump treatment procedure in a clinical trial using a short-acting version of
EPODURE in anemic subjects. The Company announced positive initial results in its Phase I/II clinical trial for its long-acting version of
EPODURE, designed to produce and deliver a therapeutic dose of EPO steadily for three to six months or more, which commenced in August 2008.
The Company plans to follow with a clinical trial of INFRADURE in 2009.
    Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major
pharmaceutical and/or medical device companies, starting with EPODURE and INFRADURE. 
    Beyond these, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly
growing global protein therapy market, which is forecast to reach US $87 billion by 2010. Other potential areas include multiple sclerosis
(interferon-*), haemophilia (Factor XIII), paediatric growth hormone deficiency (human growth hormone) and diabetes (insulin). 
    Founded in 2000, Medgenics is a US-incorporated company with major operations in Misgav, Israel. Medgenics was admitted to AIM in
December 2007 and currently trades under two separate lines on the AIM market; the Reg.S restricted securities trade under the TIDM (AIM:
MEDG) and the unrestricted securities trade under the TIDM (AIM:MEDU).
    www.medgenics.com 

    CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
    This release contains forward-looking statements, which include all statements other than statements of historical fact, including
(without limitation) those regarding the Company's financial position, business strategy, plans and objectives of management for future
operations. These statements relate to future events, prospects, developments and strategies. Forward-looking statements are sometimes
identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable
terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of
these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to
reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such
statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not
occur.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCPUGMAPUPRPPP
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Medgenics(Regs) Charts.